BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cardinal Health (CAH) Commences Tender Offer To Acquire ALARIS Medical Systems; $2 Billion


10/19/2005 5:11:33 PM

DUBLIN, Ohio and SAN DIEGO, June 1 /PRNewswire-FirstCall/ -- Cardinal Health, Inc. and ALARIS Medical Systems, Inc. today announced that, on Friday, May 28, 2004, a subsidiary of Cardinal Health commenced its previously announced tender offer to acquire all of the outstanding common shares of ALARIS, at a price of $22.35 per share, net to the seller in cash. The tender offer is scheduled to expire at midnight, New York City time, on Friday, June 25, 2004, unless extended.

On May 18, Cardinal Health and ALARIS announced that they had reached an agreement for Cardinal Health to acquire ALARIS in a transaction valued at approximately $2 billion, including the assumption of outstanding debt. The transaction is expected to be completed by June 30, 2004 and consists of a cash tender offer to be followed by a merger. Upon completion of the merger, ALARIS will become a wholly owned subsidiary of Cardinal Health.

The ALARIS Board of Directors has approved the Cardinal Health tender offer, the merger and the merger agreement and unanimously recommends that ALARIS stockholders accept the Cardinal Health tender offer and tender their shares.

Completion of the tender offer is subject to there being validly tendered at least that number of ALARIS shares (disregarding any shares tendered by any officer or director of ALARIS), equal to one share more than the number of shares equal to (A) ALARIS' majority stockholder's shares plus (B) a majority of the then issued and outstanding ALARIS shares (other than ALARIS shares owned beneficially or of record by ALARIS' majority stockholder or directors or executive officers of ALARIS) (which number, as of May 27, 2004, equaled 59,183,803 ALARIS shares). The tender offer is also subject to obtaining certain regulatory clearances and approvals and other customary conditions. In this connection, Cardinal Health has made filings under the Hart-Scott- Rodino Antitrust Improvements Act as well as the required filing with German competition authorities and expects to receive the necessary clearances before the end of June 2004.

The complete terms and conditions of the Cardinal Health tender offer for ALARIS are set forth in the Offer to Purchase, dated May 28, 2004, and the related Letter of Transmittal, copies of which are available by contacting the information agent, MacKenzie Partners, Inc. at (800) 322-2885 (Toll-Free) or at (212) 929-5500 (Collect) or by email at: proxy@mackenziepartners.com.

About ALARIS Medical Systems

ALARIS Medical Systems ( http://www.alarismed.com/ ) develops and markets products for the safe delivery of intravenous (IV) medications. The Company's IV medication and infusion therapy delivery systems, software applications, needle-free disposables and related monitoring equipment are marketed in the United States and internationally. ALARIS' "smart" pumps, with the proprietary Guardrails(R) Safety Software, help to reduce the risks and costs of medication errors, help to safeguard patients and clinicians and gather and record clinical information for review, analysis and interpretation. The Company provides its products, professional and technical support and training services to over 5,000 hospital and health care systems, as well as alternative care sites, in more than 120 countries through its direct sales force and distributors. Headquartered in San Diego, California, ALARIS employs approximately 3,000 people worldwide.

About Cardinal Health

Cardinal Health, Inc. ( http://www.cardinal.com/ ) is the leading provider of products and services supporting the health care industry. Cardinal Health develops, manufactures, packages and markets products for patient care; develops drug-delivery technologies; distributes pharmaceuticals, medical- surgical and laboratory supplies; and offers consulting and other services that improve quality and efficiency in health care. Headquartered in Dublin, Ohio, Cardinal Health employs more than 50,000 people on five continents and produces annual revenues of more than $50 billion. Cardinal Health is ranked #17 on the 2004 Fortune 500 list and was named one of the best U.S. companies by Forbes magazine for 2004.

Except for historical information, all other information in this news release consists of forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in Cardinal Health's Form 10-K, Form 8-K and Form 10-Q reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited to) the costs, difficulties, and uncertainties related to the integration of acquired businesses, the loss of one or more key customer or supplier relationships or changes to the terms of those relationships, changes in the distribution patterns or reimbursement rates for health-care products and/or services, the costs and other effects of governmental regulation and legal and administrative proceedings, and general economic and market conditions. Cardinal Health undertakes no obligation to update or revise any forward- looking statement.

This announcement is neither an offer to purchase nor a solicitation of an offer to sell securities of ALARIS Medical Systems. Cardinal Health has filed a tender offer statement with the U.S. Securities and Exchange Commission and ALARIS has filed a solicitation/recommendation statement with respect to the Cardinal Health tender offer. Investors and ALARIS stockholders are strongly advised to read the tender offer statement (including the offer to purchase, letter of transmittal and related tender documents) and the related solicitation/recommendation statement because they will contain important information. The offer to purchase, the related letter of transmittal and certain other offer documents, as well as the solicitation/recommendation statement, are available to all stockholders of ALARIS at no expense to them. These documents are also available at no charge at the SEC's website at http://www.sec.gov/ .

Cardinal Health, Inc.

CONTACT: Media, Jim Mazzola, +1-614-757-3690, orjim.mazzola@cardinal.com , or Investors, Jim Hinrichs, +1-614-757-7828, orjim.hinrichs@cardinal.com , both of Cardinal Health, Inc.; or Media, FrankJepson, +1-858-458-7448, or fjepson@alarismed.com , or Investors, WilliamBopp, +1-858-458-7994, or wbopp@alarismed.com , both of ALARIS MedicalSystems, Inc.



Read at Reuters
Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES